Glaukos Corp key statistics and ratios
In fiscal 2025, Glaukos Corp had return on equity of -26.4%, an operating margin of -39.3%, debt equal to 0.0% of equity and a current ratio of 4.69. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 87.9% | 75.0% | 81.9% | 85.9% | 86.8% | 86.2% | 83.7% | 59.2% | 77.3% | 75.6% | 76.0% | 75.5% | 55.7% | 64.8% |
| Operating margin | −67.8% | −28.9% | −14.4% | 3.7% | −1.4% | −7.2% | −21.2% | −54.9% | −11.2% | −29.1% | −40.9% | −31.9% | −39.3% | −25.5% |
| Net margin | −60.3% | −26.6% | −51.9% | 4.0% | −0.1% | −7.1% | 6.5% | −53.5% | −16.9% | −35.1% | −42.8% | −38.2% | −37.0% | −24.6% |
| Free-cash-flow margin | −67.6% | −17.5% | −4.3% | 5.3% | 12.4% | 4.7% | −2.1% | −13.3% | −7.8% | −22.4% | −24.8% | −17.6% | −4.4% | 5.2% |
| Return on equity | — | — | — | 4.3% | −0.1% | −8.3% | 3.6% | −18.0% | −7.9% | −17.8% | −27.2% | −23.8% | −26.4% | −24.7% |
| Return on assets | — | −46.6% | −52.2% | 3.6% | −0.1% | −6.9% | 3.0% | −13.2% | −4.8% | −9.7% | −13.9% | −15.3% | −20.1% | −18.1% |
| Asset turnover | — | 1.75 | 1.00 | 0.91 | 1.06 | 0.97 | 0.46 | 0.25 | 0.29 | 0.28 | 0.32 | 0.40 | 0.54 | 0.74 |
| Current ratio | — | 0.52 | 5.11 | 7.09 | 5.58 | 5.81 | 4.56 | 9.45 | 7.67 | 6.13 | 5.34 | 5.99 | 4.69 | 4.57 |
| Debt to equity | — | — | 10.2% | 2.6% | 0.0% | 0.0% | 0.0% | 28.4% | 47.7% | 53.1% | 61.2% | 7.4% | 0.0% | 0.0% |
| Interest cover (operating income ÷ interest) | — | — | — | — | — | — | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m |
| Effective tax rate | — | — | — | 0.9% | — | — | — | — | — | — | — | — | — | — |
| R&D as % of revenue | 74.1% | 42.1% | 34.9% | 25.5% | 24.4% | 27.4% | 28.8% | 38.0% | 34.4% | 43.6% | 44.1% | 35.6% | 29.7% | 29.2% |
| SG&A as % of revenue | 81.6% | 61.7% | 61.3% | 56.6% | 60.4% | 65.9% | 74.5% | 76.2% | 61.0% | 68.2% | 71.2% | 68.1% | 65.4% | 63.0% |
| Capital spending as % of revenue | 4.1% | 1.9% | 1.2% | 5.5% | 4.0% | 5.7% | 2.0% | 3.1% | 16.3% | 10.7% | 6.4% | 1.6% | 1.5% | 1.7% |
| Free cash flow ÷ net income | — | — | — | 133.4% | — | — | −33.0% | — | — | — | — | — | — | — |
| Quarter | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 | 2026 Q3Sept 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 72.9% | 77.2% | 78.3% | 78.4% | −1.1% | 77.9% | 81.7% | 85.2% |
| Operating margin | −27.2% | −19.4% | −18.3% | −12.3% | −97.7% | −13.2% | −9.3% | 0.4% |
| Net margin | −31.8% | −17.0% | −15.8% | −12.2% | −93.4% | −13.1% | −9.9% | 1.0% |
| Free-cash-flow margin | −1.2% | −19.2% | 4.7% | −8.8% | 2.7% | −10.9% | 6.5% | 17.3% |
| Current ratio | 5.99 | 6.49 | 5.51 | 5.20 | 4.69 | 5.43 | 5.04 | 4.57 |
| R&D as % of revenue | 34.6% | 30.3% | 29.4% | 20.1% | 52.4% | 29.3% | 27.6% | 14.7% |
| SG&A as % of revenue | 65.4% | 66.3% | 67.2% | 62.2% | 66.2% | 61.7% | 62.5% | 62.0% |
Financial health
- Short-term assets cover short-term liabilities $580m of assets due within a year against $127m of liabilities due within a year.
- Short-term assets cover long-term liabilities $580m short-term assets against $136m of longer-dated liabilities.
- More cash than debt Cash or debt not separately reported. Not assessable.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
- Operating profit covers interest at least five times over Operating income of −$176m against $5m of interest.
Moat
Weak moat
How hard Glaukos's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 0 / 20
Cash operating profit has been a median 1.9% of total assets over 10 years.
- Pricing power 14 / 20
Gross margin has been a median 76.5%, moving by 8.5 percentage points (standard deviation) across 10 years.
- Durability 10 / 20
Operating margin has been a median -18.4%; its worst year was -40.8%.
- Cash conversion 4 / 20
Free cash flow was positive in 4 of 10 years, at a median -3.0% of revenue.
- Discipline 0 / 20
The diluted share count rose 26.3% over five years; stock-based pay has been a median 13.1% of revenue.
AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.
Compare with peers
- Transmedics Group, Inc. statistics
- Novocure Ltd statistics
- Myriad Genetics Inc statistics
- Bioventus Inc. statistics
- Irhythm Holdings, Inc. statistics
Head to head: GKOS vs TMDXGKOS vs NVCRGKOS vs MYGNBVS vs GKOS
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies